EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Achievement of HbA1c and weight targets in adults with type 2 diabetes on once weekly injectable glucagon‐like peptide‐1 receptor agonist therapy in UK primary care: A retrospective, real‐world study

Kunal Gulati, Katrien Wijndaele, Joanne Webb, Lill-Brith von Arx, Monica Seif, Thomas Jennison, Antonia Geneidat, Rosie Wild, Robert Wood, Kamlesh Khunti iD

Diabetes, Obesity and Metabolism · 2025-04 · 27 (4) · 2086-2095

DOI: 10.1111/dom.16201 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 22.01.2025. Verfasst von Kunal Gulati und 9 weiteren Autor:innen. Beteiligte Einrichtung: Eli Lilly and Company Limited, Basingstoke, UK. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glycated Hemoglobin, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims Evaluate glycated haemoglobin (HbA1c) and weight changes after 6 months of once‐weekly (QW) injectable glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) therapy in UK primary care. Materials and Methods Retrospective, non‐interventional study, using the Clinical Practice Research Datalink Aurum primary care database, identified adults with type 2 diabetes (T2D) newly initiating a QW injectable GLP‐1 RA between January 2020 and November 2021. Dual primary outcomes were proportion of patients with (1) HbA1c < 7% (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glycated HemoglobinGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsHumansRetrospective StudiesMiddle AgedMaleFemalePrimary Health CareUnited KingdomAgedWeight LossBody WeightAdultDrug Administration ScheduleTreatment Outcome

Stichwörter der Autor:innen

GLP‐1 analogueglycaemic controlprimary caretype 2 diabetesweight control

Substanzen

Glycated HemoglobinGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agentshemoglobin A1c protein, human

Autor:innen und Institutionen

  • Eli Lilly and Company Limited, Basingstoke, UK.
  • Eli Lilly and Company, Herlev, Denmark.
  • Adelphi Real World, Bollington, UK.
  • Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK.

ORCID-Profile: Kamlesh Khunti

Förderung

  • Eli Lilly and Company

Zitieren

APA

Gulati, K., Wijndaele, K., Webb, J., von Arx, L. B., Seif, M., Jennison, T., Geneidat, A., Wild, R., Wood, R., & Khunti, K. (2025). Achievement of HbA1c and weight targets in adults with type 2 diabetes on once weekly injectable glucagon‐like peptide‐1 receptor agonist therapy in UK primary care: A retrospective, real‐world study. Diabetes, Obesity and Metabolism, 27(4), 2086-2095. https://doi.org/10.1111/dom.16201

Vancouver

Gulati K, Wijndaele K, Webb J, von Arx LB, Seif M, Jennison T, et al. Achievement of HbA1c and weight targets in adults with type 2 diabetes on once weekly injectable glucagon‐like peptide‐1 receptor agonist therapy in UK primary care: A retrospective, real‐world study. Diabetes, Obesity and Metabolism. 2025;27(4):2086-2095. doi:10.1111/dom.16201

BibTeX
@article{Gulati2025,
  author = {Gulati, Kunal and Wijndaele, Katrien and Webb, Joanne and von Arx, Lill-Brith and Seif, Monica and Jennison, Thomas and Geneidat, Antonia and Wild, Rosie and Wood, Robert and Khunti, Kamlesh},
  title = {Achievement of HbA1c and weight targets in adults with type 2 diabetes on once weekly injectable glucagon‐like peptide‐1 receptor agonist therapy in UK primary care: A retrospective, real‐world study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  volume = {27},
  number = {4},
  pages = {2086--2095},
  doi = {10.1111/dom.16201}
}
Kostenlos starten →